P2Y<sub>1</sub> receptor | P2Y receptors | IUPHAR/MMV Guide to MALARIA PHARMACOLOGY

Top ▲

P2Y1 receptor

Target id: 323

Nomenclature: P2Y1 receptor

Family: P2Y receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 373 3q25.2 P2RY1 purinergic receptor P2Y1 1,27
Mouse 7 373 3 E1 P2ry1 purinergic receptor P2Y 51
Rat 7 373 2q31 P2ry1 purinergic receptor P2Y1 51
Previous and Unofficial Names
ATP receptor | P2 purinoceptor subtype Y1 | P2Y purinoceptor 1 | platelet ADP receptor | Purinergic receptor P2Y1 | P2Y ATP receptor 1 | P2Y1 receptor | purinergic receptor P2Y
Database Links
Specialist databases
GPCRDB p2ry1_human (Hs), p2ry1_mouse (Mm), p2ry1_rat (Rn)
Other databases
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein
Natural/Endogenous Ligands
Potency order of endogenous ligands

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[3H]2MeSADP Hs Agonist 7.3 pKd 49
pKd 7.3 (Kd 4.9x10-8 M) [49]
MRS2365 Hs Agonist 9.4 pEC50 7
pEC50 9.4 [7]
2-Cl-ADP(α-BH3) Hs Agonist 8.1 pEC50 2
pEC50 8.1 (EC50 7x10-9 M) [2]
compound 3a [PMID: 22873688] Mg Full agonist 7.4 pEC50 54
pEC50 7.4 (EC50 3.8x10-8 M) [54]
ADPβS Hs Agonist 7.3 pEC50 49
pEC50 7.3 (EC50 4.99x10-8 M) [49]
2',3'-ddATP Hs Partial agonist 8.0 pIC50 43
pIC50 8.0 [43]
dATPαS Hs Partial agonist 7.7 pIC50 43
pIC50 7.7 [43]
ATPγS Hs Partial agonist 7.4 pIC50 43
pIC50 7.4 [43]
2MeSATP Hs Partial agonist 6.4 – 7.6 pIC50 43,52
pIC50 6.4 – 7.6 [43,52]
ATP Hs Partial agonist 6.1 – 7.8 pIC50 43,52
pIC50 6.1 – 7.8 [43,52]
ADP Hs Full agonist 6.2 – 7.2 pIC50 43,52
pIC50 6.2 – 7.2 [43,52]
2MeSADP Hs Full agonist 5.4 – 7.0 pIC50 43,52
pIC50 5.4 – 7.0 [43,52]
[35S]ADPβS ? Agonist - -
View species-specific agonist tables
Agonist Comments
When the purified recombinant human P2Y1 receptor was reconstituted in liposomes, 2-meSADP, 2-meSATP and ADP were full agonists and ATPγS, ADPβS and ATP were partial agonists [53]. This confirms an earlier study that ATP is a partial agonist [38], so at higher levels of P2Y1 receptor expression ATP acts as an agonist and at low levels as an antagonist [23] (see Antagonist section). Note that in some cases the apparent agonist action of ATP and other triphosphates may be due to impurity and to the rapid conversion to the diphosphate form [23].
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[32P]MRS2500 Hs Antagonist 9.4 pKd 26
pKd 9.4 [26]
[3H]MRS2279 Hs Antagonist 8.1 pKd 52
pKd 8.1 (Kd 8x10-9 M) [52]
MRS2500 Hs Antagonist 8.8 – 9.1 pKi 6,29
pKi 8.8 – 9.1 [6,29]
BMS compound 4c Hs Antagonist 8.2 pKi 41
pKi 8.2 (Ki 7x10-9 M) [41]
Pfizer compound 67 [PMID:18445527] Hs Antagonist 8.0 pKi 39
pKi 8.0 (Ki 1x10-8 M) [39]
MRS2279 Hs Antagonist 7.9 pKi 52
pKi 7.9 [52]
MRS2298 Hs Antagonist 7.5 pKi 6
pKi 7.5 [6]
Pfizer compound 11 [PMID:18445527] Hs Antagonist 7.3 pKi 39
pKi 7.3 (Ki 5x10-8 M) [39]
GlaxoSmithKline compound 6i [PMID:18926700] Hs Antagonist 7.2 pKi 37
pKi 7.2 (Ki 7x10-8 M) [37]
MRS2496 Hs Antagonist 7.1 pKi 6
pKi 7.1 [6]
MRS2179 Hs Antagonist 7.0 – 7.1 pKi 3,52
pKi 7.0 – 7.1 [3,52]
GlaxoSmithKline compound 5h [PMID:20542694] Hs Antagonist 6.8 pKi 50
pKi 6.8 (Ki 1.4x10-7 M) [50]
2-chloroadenosine-5-triphosphate Hs Antagonist 5.6 pKi 23
pKi 5.6 [23]
suramin Hs Antagonist 5.3 pKi 52
pKi 5.3 [52]
2MeSATP Hs Antagonist 5.2 pKi 23
pKi 5.2 [23]
PPADS Hs Antagonist 5.2 pKi 52
pKi 5.2 [52]
ATP Hs Antagonist 4.8 pKi 23
pKi 4.8 [23]
A2P5P Hs Antagonist 5.8 pEC50 3
pEC50 5.8 [3]
adenosine-3'-5'-bisphosphate Hs Antagonist 5.6 pEC50 3
pEC50 5.6 [3]
MRS2950 Hs Antagonist 6.9 pIC50 9
pIC50 6.9 (IC50 1.4x10-7 M) [9]
Antagonist Comments
ATP is a partial agonist [38,53], so at low levels of P2Y1 receptor expression it acts as an antagonist [23]. Similarly, while 2MeSATP is considered to be a full agonist at the purified P2Y1 receptor [53], it has also been shown to act as an competitive antagonist at the same receptor [23]. High-throughput screening against the P2Y1 receptor identified a novel series of tetrahydro-4-quinolinamine antagonists [37].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
BMS compound 16 [PMID:23368907] Hs Negative 6.9 pKi 57
pKi 6.9 (Ki 1.2x10-7 M) [57]
Description: Inhibition of [3H]2MeSADP binding to P2Y1 receptors expressed in COS-7 cells.
2,2'-pyridylisatogen tosylate Hs Negative 6.8 pIC50 19
pIC50 6.8 (IC50 1.4x10-7 M) [19]
Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
Comments:  The activation of PLC leads to mobilisation of calcium from IP3-sensitive intracellular stores. Purified recombinant human P2Y1 receptors coupled to Gαq and Gα11, but not Gα0, Gαi1, Gαi2 or Gαi3.
References:  11,53
Secondary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Potassium channel
Comments:  In CHO cells stably expressing CFTR, the endogenous P2Y1 receptor shifts its coupling to Gi/Go [35]
References:  16,32
Tissue Distribution
Nucleus accumbens >> putamen > caudate nucleus, striatum > parahippocampal gyrus > hypothalamus, globus pallidus > cingulate gyrus, hippocampus > amygdala, medula oblongata > cerebellum, locus coeruleus, medial frontal gyrus, superior frontal gyrus, spinal cord > thalamus > substantia nigra.
Species:  Human
Technique:  RT-PCR.
References:  36
Placenta > prostate > brain > intestine > skeletal muscle, heart > macrophages > pituitary, lung > pancreas > spleen, foetal liver > adipose> stomach, lymphocytes > liver, kidney.
Species:  Human
Technique:  RT-PCR.
References:  36
Blood platelets.
Species:  Human
Technique:  RT-PCR
References:  28,34
GI tract: myenteric plexus, submucosal plexus, intestinal crypts of the ileum and along the lumen of the villi.
Species:  Mouse
Technique:  in situ hybridisation.
References:  20
Heart, skeletal muscle > brain, spleen, lung, liver, kidney.
Species:  Rat
Technique:  Northern blotting.
References:  51
Sensory ganglia: dorsal root ganglia (DRG), nodose ganglion (NG) and trigeminal ganglion (TG).
Species:  Rat
Technique:  RT-PCR and Immunohistochemistry.
References:  40
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Voltage clamp technique used to measure the ATP-evoked membrane current in Xenopus oocytes transfected with the P2Y1 receptor.
Species:  Rat
Tissue:  Xenopus oocytes.
Response measured:  Membrane current produced.
References:  51
Measurement of [Ca2+]i levels in Jurkat cells transfected with the P2Y1 receptor.
Species:  Human
Tissue:  Jurkat cells.
Response measured:  Increase in [Ca2+]i levels.
References:  22,34
Measurement of N-type Ca2+ channel currents in rat superior cervical ganglion (SCG) cells expressing the rat P2Y1 receptor.
Species:  Rat
Tissue:  Rat SCG cells.
Response measured:  Inhibition of N-type Ca2+ currents.
References:  15
Measurement of [Ca2+]i in human astrocytoma cells stably expressing the human P2Y1 receptor.
Species:  Human
Tissue:  1321N1 human astrocytoma cells.
Response measured:  Rapid increase in [Ca2+]i.
References:  38
Measurement of [Ca2+]i in rat glioma C6 cells endogenously expressing P2Y1 and P2Y2 receptors.
Species:  Rat
Tissue:  Glioma C6 cells.
Response measured:  Increase in [Ca2+]i via depletion of IP3-sensitive intracellular Ca2+ stores (PLC stimulation) and influx of extracellular Ca2+.
References:  42
Measurement of IP3 levels in response to selective P2Y1 receptor agonists in HEK 293 cells endogenously expressing the P2Y1 and P2Y2 receptors.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Increase in IP3 accumulation.
References:  44
Measurement of Ca2+ levels in response to the P2Y1 agonist ADP in mouse peritoneal macrophages.
Species:  Mouse
Tissue:  Peritoneal macrophages.
Response measured:  Increase in [Ca2+]i.
References:  10
Measurement of K2+ current using patch-clamping of SCG cells transfected with the P2Y1 receptor and GIRK1 and GIRK2 channels.
Species:  Rat
Tissue:  SCG neurons.
Response measured:  Transient activation of GIRK current followed by inactivation.
References:  47
Following mechanical stimulation of an individual 1321N1 cell, measurement of Ca2+ propagation in 1321N1 cells transfected with the P2Y1 cells.
Species:  Rat
Tissue:  1321N1 cells.
Response measured:  Ca2+ wave only spread to cells expressing the P2Y1 receptor. P2Y1 is not required for the initiation of the wave.
References:  18
Measurement of K+ currents in primary cultures of pyramidal hippocampal neurons
Species:  Rat
Tissue:  Hippocampal primary neurons
Response measured:  Inhibition of the M-type K+ current
References:  16
Physiological Functions
Mitogenic effects.
Species:  Rat
Tissue:  Aortic smooth muscle cells.
References:  13
Smooth muscle relaxation.
Species:  Mouse
Tissue:  GI tract: stomach fundus, duodenum, ileum and colon.
References:  20
Vasodilation through the NO/cGMP pathway.
Species:  Rat
Tissue:  Arterial mesenteric bed.
References:  5
Platelet shape change.
Species:  Human
Tissue:  Platelets.
References:  28
Induction of platelet aggregation.
Species:  Human
Tissue:  Blood platelets.
References:  22
Release of IL-6 stimulation and enhanced neuroprotection
Species:  Rat
Tissue:  Primary hippocampal astrocytes
References:  17
GFAP and GDNF production under ischemic conditions
Species:  Rat
Tissue:  Astrocytes
References:  48
Atherosclerosis enhancement
Species:  Mouse
Tissue:  Aorta
References:  21
Glutamate efflux
Species:  Rat
Tissue:  Spinal cord astrocytes
References:  56
Endothelial cell migration
Species:  Human
Tissue:  HUVEC
References:  45
Regulation of EGF activity
Species:  Human
Tissue:  Epithelial cells
References:  4
Physiological Consequences of Altering Gene Expression
P2Y1 receptor knockout mice show no obvious abnormalities in their development, survival or reproduction, and have normal platelet morphology and count.
However, they have inpaired platelet aggregation in response to ADP and other agonists, and resistance to thromboembolism.
Species:  Mouse
Technique:  Gene targeting in embryonic stem cells.
References:  33
P2Y1 receptor deficiency resulted in a reduction of atherosclerosis in ApoE knockout mice.
Species:  Mouse
Technique:  Gene targeting in embryonic stem cells.
References:  21
P2Y1 receptor knockout mice exhibit increased bleeding time and increased protection from collagen- and ADP-induced thromboembolism.
Species:  Mouse
Technique:  Gene targeting in embryonic stem cells.
References:  14
In vivo knockdown of the P2Y1 receptor by administration of short hairpin RNA selectively impairs the migration of neural progenitors to the subventricular zone
Species:  Mouse
Technique:  RNAi
References:  32
P2Y1 knockout mice are protected from renal disease and resistant to capillary loss during passive crescentic glomerulonephritis
Species:  Mouse
Technique:  Knockout by gene targeting in embryonic stem cells
References:  25
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
P2ry1tm1Gac P2ry1tm1Gac/P2ry1tm1Gac
involves: 129S2/SvPas * C57BL/6
MGI:105049  MP:0002551 abnormal blood coagulation PMID: 10606627 
P2ry1tm1Bhk P2ry1tm1Bhk/P2ry1tm1Bhk
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
MGI:105049  MP:0005464 abnormal platelet physiology PMID: 10502826 
P2ry1tm1Bhk P2ry1tm1Bhk/P2ry1tm1Bhk
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
MGI:105049  MP:0003422 abnormal thrombolysis PMID: 10502826 
P2ry1tm1Gac P2ry1tm1Gac/P2ry1tm1Gac
involves: 129S2/SvPas * C57BL/6
MGI:105049  MP:0009549 decreased platelet aggregation PMID: 10606627 
P2ry1+|P2ry1tm1Gac P2ry1tm1Gac/P2ry1+
involves: 129S2/SvPas * C57BL/6
MGI:105049  MP:0009549 decreased platelet aggregation PMID: 10606627 
P2ry1tm1Gac P2ry1tm1Gac/P2ry1tm1Gac
involves: 129S2/SvPas * C57BL/6
MGI:105049  MP:0005606 increased bleeding time PMID: 10606627 
P2ry1tm1Bhk P2ry1tm1Bhk/P2ry1tm1Bhk
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
MGI:105049  MP:0005606 increased bleeding time PMID: 10502826 
Biologically Significant Variants
Type:  Single nucleotide polymorphism
Species:  Human
Description:  A silent polymorphism in the coding seguence of the P2Y1 gene is associated with different platelet reactivity to ADP
References:  24
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The presence of a polymorphism appears to confer an attenuated antiplatelet effect during aspirin treatment in healthy Chinese subjects
References:  31
General Comments
In all species, the P2Y1 receptor is selective for adenine nucleotides. Presence of P2Y1 receptors has been reported in mitochondria of astrocytes and C6 cells, although its role in these sub-cellular structures remains unclear [30]. 44% of P2Y1 receptors expressed by HEK293 cell membranes exist as dimers in the resting state [8]. Furthermore, P2Y1 receptors appear to form heterodimers with novel pharmacological and signalling properties with a number of other receptors, including P2Y11 [12], P2Y12 [46] and A1 adenosine receptors [55].


Show »

1. Ayyanathan K, Webbs TE, Sandhu AK, Athwal RS, Barnard EA, Kunapuli SP. (1996) Cloning and chromosomal localization of the human P2Y1 purinoceptor. Biochem. Biophys. Res. Commun., 218 (3): 783-8. [PMID:8579591]

2. Azran S, Förster D, Danino O, Nadel Y, Reiser G, Fischer B. (2013) Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists. J. Med. Chem., 56 (12): 4938-52. [PMID:23751098]

3. Boyer JL, Romero-Avila T, Schachter JB, Harden TK. (1996) Identification of competitive antagonists of the P2Y1 receptor. Mol. Pharmacol., 50 (5): 1323-9. [PMID:8913364]

4. Buvinic S, Bravo-Zehnder M, Boyer JL, Huidobro-Toro JP, González A. (2007) Nucleotide P2Y1 receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells. J. Cell. Sci., 120 (Pt 24): 4289-301. [PMID:18057028]

5. Buvinic S, Briones R, Huidobro-Toro JP. (2002) P2Y(1) and P2Y(2) receptors are coupled to the NO/cGMP pathway to vasodilate the rat arterial mesenteric bed. Br. J. Pharmacol., 136 (6): 847-56. [PMID:12110609]

6. Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, Lombardi R, Bischofberger N, Harden TK, Jacobson KA. (2004) Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem. Pharmacol., 68 (10): 1995-2002. [PMID:15476670]

7. Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK. (2004) Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J. Pharmacol. Exp. Ther., 311 (3): 1038-43. [PMID:15345752]

8. Choi RC, Simon J, Tsim KW, Barnard EA. (2008) Constitutive and agonist-induced dimerizations of the P2Y1 receptor: relationship to internalization and scaffolding. J. Biol. Chem., 283 (16): 11050-63. [PMID:18270199]

9. Costanzi S, Santhosh Kumar T, Balasubramanian R, Kendall Harden T, Jacobson KA. (2012) Virtual screening leads to the discovery of novel non-nucleotide P2Y₁ receptor antagonists. Bioorg. Med. Chem., 20 (17): 5254-61. [PMID:22831801]

10. Coutinho-Silva R, Ojcius DM, Górecki DC, Persechini PM, Bisaggio RC, Mendes AN, Marks J, Burnstock G, Dunn PM. (2005) Multiple P2X and P2Y receptor subtypes in mouse J774, spleen and peritoneal macrophages. Biochem. Pharmacol., 69 (4): 641-55. [PMID:15670583]

11. Ding Z, Tuluc F, Bandivadekar KR, Zhang L, Jin J, Kunapuli SP. (2005) Arg333 and Arg334 in the COOH terminus of the human P2Y1 receptor are crucial for Gq coupling. Am. J. Physiol., Cell Physiol., 288 (3): C559-67. [PMID:15509659]

12. Ecke D, Hanck T, Tulapurkar ME, Schäfer R, Kassack M, Stricker R, Reiser G. (2008) Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. Biochem. J., 409 (1): 107-16. [PMID:17824841]

13. Erlinge D, Hou M, Webb TE, Barnard EA, Moller S. (1998) Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. Biochem. Biophys. Res. Commun., 248: 864-870. [PMID:9704019]

14. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. (1999) Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat. Med., 5 (10): 1199-202. [PMID:10502826]

15. Filippov AK, Brown DA, Barnard EA. (2000) The P2Y(1) receptor closes the N-type Ca(2+) channel in neurones, with both adenosine triphosphates and diphosphates as potent agonists. Br. J. Pharmacol., 129 (6): 1063-6. [PMID:10725253]

16. Filippov AK, Choi RC, Simon J, Barnard EA, Brown DA. (2006) Activation of P2Y1 nucleotide receptors induces inhibition of the M-type K+ current in rat hippocampal pyramidal neurons. J. Neurosci., 26 (36): 9340-8. [PMID:16957090]

17. Fujita T, Tozaki-Saitoh H, Inoue K. (2009) P2Y1 receptor signaling enhances neuroprotection by astrocytes against oxidative stress via IL-6 release in hippocampal cultures. Glia, 57 (3): 244-57. [PMID:18756525]

18. Gallagher CJ, Salter MW. (2003) Differential properties of astrocyte calcium waves mediated by P2Y1 and P2Y2 receptors. J. Neurosci., 23 (17): 6728-39. [PMID:12890765]

19. Gao ZG, Mamedova L, Tchilibon S, Gross AS, Jacobson KA. (2004) 2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. Biochem. Pharmacol., 68 (2): 231-7. [PMID:15193995]

20. Giaroni C, Knight GE, Ruan HZ, Glass R, Bardini M, Lecchini S, Frigo G, Burnstock G. (2002) P2 receptors in the murine gastrointestinal tract. Neuropharmacology, 43 (8): 1313-23. [PMID:12527481]

21. Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP, Gachet C. (2008) Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors. Circulation, 118 (7): 754-63. [PMID:18663083]

22. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. (1998) The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood, 92: 152-159. [PMID:9639511]

23. Hechler B, Vigne P, Léon C, Breittmayer JP, Gachet C, Frelin C. (1998) ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol. Pharmacol., 53 (4): 727-33. [PMID:9547364]

24. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. (2005) Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler. Thromb. Vasc. Biol., 25 (1): 252-7. [PMID:15514209]

25. Hohenstein B, Renk S, Lang K, Daniel C, Freund M, Léon C, Amann KU, Gachet C, Hugo CP. (2007) P2Y1 gene deficiency protects from renal disease progression and capillary rarefaction during passive crescentic glomerulonephritis. J. Am. Soc. Nephrol., 18 (2): 494-505. [PMID:17215444]

26. Houston D, Ohno M, Nicholas RA, Jacobson KA, Harden TK. (2006) [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br. J. Pharmacol., 147 (5): 459-67. [PMID:16299552]

27. Janssens R, Communi D, Pirotton S, Samson M, Parmentier M, Boeynaems JM. (1996) Cloning and tissue distribution of the human P2Y1 receptor. Biochem. Biophys. Res. Commun., 221 (3): 588-93. [PMID:8630005]

28. Jin J, Daniel JL, Kunapuli SP. (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem., 273 (4): 2030-4. [PMID:9442040]

29. Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, Maddileti S, Marquez VE, Harden TK, Jacobson KA. (2003) 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J. Med. Chem., 46 (23): 4974-87. [PMID:14584948]

30. Krzeminski P, Misiewicz I, Pomorski P, Kasprzycka-Guttman T, Barańska J, Brańska J. (2007) Mitochondrial localization of P2Y1, P2Y2 and P2Y12 receptors in rat astrocytes and glioma C6 cells. Brain Res. Bull., 71 (6): 587-92. [PMID:17292801]

31. Li Q, Chen BL, Ozdemir V, Ji W, Mao YM, Wang LC, Lei HP, Fan L, Zhang W, Liu J et al.. (2007) Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics, 8 (6): 577-86. [PMID:17559347]

32. Liu X, Hashimoto-Torii K, Torii M, Haydar TF, Rakic P. (2008) The role of ATP signaling in the migration of intermediate neuronal progenitors to the neocortical subventricular zone. Proc. Natl. Acad. Sci. U.S.A., 105 (33): 11802-7. [PMID:18689674]

33. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J. Clin. Invest., 104 (12): 1731-7. [PMID:10606627]

34. Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. (1997) The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett., 403 (1): 26-30. [PMID:9038354]

35. Marcet B, Chappe V, Delmas P, Verrier B. (2004) Pharmacological and signaling properties of endogenous P2Y1 receptors in cystic fibrosis transmembrane conductance regulator-expressing Chinese hamster ovary cells. J Pharmacol Exp Ther., 309: 533-539. [PMID:14742736]

36. Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, Emson PC, Murdock PR. (2001) Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study. Biochim. Biophys. Acta, 1521 (1-3): 107-19. [PMID:11690642]

37. Morales-Ramos AI, Mecom JS, Kiesow TJ, Graybill TL, Brown GD, Aiyar NV, Davenport EA, Kallal LA, Knapp-Reed BA, Li P et al.. (2008) Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists. Bioorg. Med. Chem. Lett., 18 (23): 6222-6. [PMID:18926700]

38. Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK. (1998) Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol. Pharmacol., 54 (6): 1118-23. [PMID:9855642]

39. Pfefferkorn JA, Choi C, Winters T, Kennedy R, Chi L, Perrin LA, Lu G, Ping YW, McClanahan T, Schroeder R et al.. (2008) P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg. Med. Chem. Lett., 18 (11): 3338-43. [PMID:18445527]

40. Ruan HZ, Burnstock G. (2003) Localisation of P2Y1 and P2Y4 receptors in dorsal root, nodose and trigeminal ganglia of the rat. Histochem. Cell Biol., 120 (5): 415-26. [PMID:14564529]

41. Ruel R, L'heureux A, Thibeault C, Daris JP, Martel A, Price LA, Wu Q, Hua J, Wexler RR, Rehfuss R et al.. (2013) New azole antagonists with high affinity for the P2Y1 receptor. Bioorg. Med. Chem. Lett., 23 (12): 3519-22. [PMID:23668989]

42. Sabala P, Czajkowski R, Przybyłek K, Kalita K, Kaczmarek L, Barańska J. (2001) Two subtypes of G protein-coupled nucleotide receptors, P2Y(1) and P2Y(2) are involved in calcium signalling in glioma C6 cells. Br. J. Pharmacol., 132 (2): 393-402. [PMID:11159687]

43. Schachter JB, Harden TK. (1997) An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Br. J. Pharmacol., 121 (2): 338-44. [PMID:9154346]

44. Schachter JB, Sromek SM, Nicholas RA, Harden TK. (1997) HEK293 human embryonic kidney cells endogenously express the P2Y1 and P2Y2 receptors. Neuropharmacology, 36 (9): 1181-7. [PMID:9364473]

45. Shen J, DiCorleto PE. (2008) ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways. Circ. Res., 102 (4): 448-56. [PMID:18174464]

46. Shrestha SS, Parmar M, Kennedy C, Bushell TJ. (2010) Two-pore potassium ion channels are inhibited by both G(q/11)- and G(i)-coupled P2Y receptors. Mol. Cell. Neurosci., 43 (4): 363-9. [PMID:20097289]

47. Simon J, Filippov AK, Göransson S, Wong YH, Frelin C, Michel AD, Brown DA, Barnard EA. (2002) Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells. J. Biol. Chem., 277 (35): 31390-400. [PMID:12080041]

48. Sun JJ, Liu Y, Ye ZR. (2008) Effects of P2Y1 receptor on glial fibrillary acidic protein and glial cell line-derived neurotrophic factor production of astrocytes under ischemic condition and the related signaling pathways. Neurosci Bull, 24 (4): 231-43. [PMID:18668152]

49. Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K. (2001) Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol, 60: 432-439. [PMID:11502873]

50. Thalji RK, Aiyar N, Davenport EA, Erhardt JA, Kallal LA, Morrow DM, Senadhi S, Burns-Kurtis CL, Marino JP. (2010) Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists. Bioorg. Med. Chem. Lett., 20 (14): 4104-7. [PMID:20542694]

51. Tokuyama Y, Hara M, Jones EM, Fan Z, Bell GI. (1995) Cloning of rat and mouse P2Y purinoceptors. Biochem Biophys Res Commun, 211: 211-218. [PMID:7779087]

52. Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji XD, Lacy J, Jacobson KA, Harden TK. (2002) Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol. Pharmacol., 62 (5): 1249-57. [PMID:12391289]

53. Waldo GL, Harden TK. (2004) Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol. Pharmacol., 65 (2): 426-36. [PMID:14742685]

54. Yelovitch S, Barr HM, Camden J, Weisman GA, Shai E, Varon D, Fischer B. (2012) Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist. J. Med. Chem., 55 (17): 7623-35. [PMID:22873688]

55. Yoshioka K, Saitoh O, Nakata H. (2001) Heteromeric association creates a P2Y-like adenosine receptor. Proc. Natl. Acad. Sci. U.S.A., 98 (13): 7617-22. [PMID:11390975]

56. Zeng JW, Liu XH, He WJ, Du L, Zhang JH, Wu XG, Ruan HZ. (2008) Inhibition of ATP-induced glutamate release by MRS2179 in cultured dorsal spinal cord astrocytes. Pharmacology, 82 (4): 257-63. [PMID:18841035]

57. Zhang D, Gao ZG, Zhang K, Kiselev E, Crane S, Wang J, Paoletta S, Yi C, Ma L, Zhang W et al.. (2015) Two disparate ligand-binding sites in the human P2Y1 receptor. Nature, 520 (7547): 317-21. [PMID:25822790]


Show »

How to cite this page

Select citation format: